PMID- 35117247
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct
TI  - Apatinib in treating patients with recurrent or metastatic nasopharyngeal 
      carcinoma who had failed prior platinum-based chemotherapy.
PG  - 6392-6401
LID - 10.21037/tcr-20-1773 [doi]
AB  - BACKGROUND: Platinum-based chemotherapy is the standard first-line treatment for 
      recurrent/metastatic nasopharyngeal carcinoma (NPC); however, there is no 
      standard regimen for those who failed first-line treatment. This study aimed to 
      evaluate the efficacy and safety of apatinib in treating patients with 
      recurrent/metastatic NPC who failed prior platinum-based chemotherapy. METHODS: 
      Patients aged 18-65 years with recurrent/metastatic NPC were treated with 
      apatinib at an initial dose of 500 mg once daily and continued until disease 
      progression, patient withdrawal, or unacceptable toxic effects. The primary 
      endpoints were clinical benefit rate (CBR) and toxicity. Secondary endpoints 
      included progression-free survival (PFS) and overall survival (OS). RESULTS: 
      Nineteen patients were enrolled in this study. At the final follow-up, the CBR 
      was 52.6% (95% CI: 29.8-76.2%) in the intention-to-treat population. The median 
      PFS and OS were 3.7 (95% CI: 0.6-6.8) months and 12.9 (95% CI: 9.3-16.5) months, 
      respectively. The most common grade 3-4 adverse events (AEs) were hand-foot 
      syndrome [3 (15.8%)], neutropenia [2 (10.5%)], proteinuria [2 (10.5%)], oral 
      mucosal pain [2 (10.5%)], hypertension [1 (5.3%)], hyponatremia [1 (5.3%)], 
      artery dissection [1 (5.3%)], and nasopharyngeal hemorrhage [1 (5.3%)]. A serious 
      AEs was reported in one patient who died of nasopharyngeal hemorrhage. Treatment 
      with apatinib did not significantly influence patient-reported quality-of-life, 
      except for nausea/vomiting and pain (P<0.05). CONCLUSIONS: Apatinib achieved 
      modest disease control with acceptable toxicity in recurrent/metastatic NPC 
      patients pretreated with platinum-based chemotherapy.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Tao, Chang-Juan
AU  - Tao CJ
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic 
      Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Medical oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic 
      Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Zhou, Ling
AU  - Zhou L
AD  - Graduate School, Guangdong Medical University, Zhanjiang, China.
FAU - Hu, Qiao-Ying
AU  - Hu QY
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic 
      Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Chen, Xiao-Zhong
AU  - Chen XZ
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic 
      Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8799112
OTO - NOTNLM
OT  - Apatinib
OT  - nasopharyngeal carcinoma (NPC)
OT  - platinum-based chemotherapy
OT  - recurrent or metastatic
OT  - toxicity
COIS- Conflicts of Interest: All the authors have completed the ICMJE uniform 
      disclosure form (available at http://dx.doi.org/10.21037/tcr-20-1773). The 
      authors have no conflicts of interest to declare.
EDAT- 2020/10/01 00:00
MHDA- 2020/10/01 00:01
PMCR- 2020/10/01
CRDT- 2022/02/04 05:50
PHST- 2020/04/06 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2022/02/04 05:50 [entrez]
PHST- 2020/10/01 00:00 [pubmed]
PHST- 2020/10/01 00:01 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - tcr-09-10-6392 [pii]
AID - 10.21037/tcr-20-1773 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Oct;9(10):6392-6401. doi: 10.21037/tcr-20-1773.